Braidwell LP Acquires New Stake in Oculis Holding AG $OCS

Braidwell LP bought a new position in shares of Oculis Holding AG (NASDAQ:OCS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 834,183 shares of the company’s stock, valued at approximately $11,570,000. Braidwell LP owned approximately 1.44% of Oculis at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Oculis in the second quarter valued at $393,000. Bank of America Corp DE lifted its holdings in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the period. Woodline Partners LP boosted its stake in Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new position in Oculis during the fourth quarter valued at about $1,972,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Price Performance

OCS opened at $12.02 on Thursday. The stock has a fifty day moving average of $12.59 and a 200-day moving average of $20.39. The firm has a market capitalization of $696.92 million, a P/E ratio of -6.91 and a beta of 0.52. Oculis Holding AG has a 12-month low of $10.52 and a 12-month high of $34.47. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The business had revenue of $0.38 million during the quarter. Equities analysts forecast that Oculis Holding AG will post -2.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OCS has been the subject of a number of research analyst reports. Robert W. Baird cut their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Guggenheim cut their target price on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, June 1st. JPMorgan Chase & Co. reduced their target price on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Finally, Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.